Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2019 | Pivotal safety and efficacy results for liso-cel in R/R B-NHL

Jeremy Abramson • 7 Dec 2019

ASH 2019

B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel

TRANSCEND-NHL-001

Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, discusses the pivotal safety and efficacy results from the TRANSCEND-NHL-001 study (NCT02631044). This is a phase I study evaluating lisocabtagene maraleucel (liso-cel), an investigational, anti-CD19 CAR T-cell product, in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Abramson highlights the very encouraging results, including durable clinical activity and a favorable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies

Jeremy Abramson • 12 Dec 2022

Emerging treatment strategies for patients with high-risk follicular lymphoma

Jeremy Abramson • 12 Dec 2022

Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma

Jeremy Abramson • 12 Dec 2022

TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL

Jeremy Abramson • 12 Dec 2022

Related Videos

Salvage treatment options following CAR-T failure in DLBCL

Jaromir Tomasik • 17 Apr 2024

Exploring first-line CAR-T therapy for the treatment of DLBCL

Wendy Osborne • 22 Apr 2024

CAR-T therapy as the SoC in 2L LBCL and barriers that remain

Wendy Osborne • 22 Apr 2024

The role of CAR-T therapy for lymphoma in 2024: expert session highlights

Sridhar Chaganti • 16 Apr 2024